

Increase National Institutes of Health and National Cancer Institute Funding in FY2026

Cancer Research Delivers Breakthroughs & Hope



Increased and sustained investment at NIH and NCI in the fight against cancer year over year has been key to reducing the nation's cancer mortality rate by 34% since 1991, and will bring us closer to ending cancer as we know it, for everyone.

We can't afford to lose momentum.

2 Million+

new cancer cases
projected
in 2025 for the 1st
time ever

618,120

estimated
deaths
due to cancer
in 2025



Colorectal cancer
diagnoses among
people younger than
55


4

screenable cancers
- breast, prostate,
colorectal, and
melanoma- on the
rise

18 Million+

cancer survivors in
the U.S.

NIH and NCI Funding Drive U.S. Economic Growth



In fiscal year 2024,
NIH generated

\$94.58 Billion

in new economic
activity nationwide

Return on Investment

\$1 in NIH funded research

=

\$2.56 in economic activity

supported

407,782

jobs

and

64,359

research grants

Demand for NCI Research

The growth of NCI R01
research grant applications
over the last 10 years is
almost

3x

that of the rest of
NIH combined

6 out of **7**





researcher-initiated
proposals go **unfunded**
every year

NCI HAS





13%

LESS buying power than
20 years ago

Impact of Underinvestment

-  Decline in applications funded
-  Fewer opportunities for the next generation of researchers
-  Reduced role of U.S. as the global leader in biomedical research
-  Slower pace of breakthroughs in cancer prevention, screening, and treatment

FY 2026 NCI Scientific Opportunities


-  Improving Patients’ Lives Through Symptom Science Research
-  Revolutionizing Cancer Clinical Trials
-  Clarifying the Impact of the Environment on Cancer Risk
-  Harnessing the Power of Cancer Data
-  Unraveling the Complexity of Cancer Metastasis

Recent NCI Milestones

-  **First FDA-approved Treatment**
advanced cases of alveolar soft part sarcoma
-  **Development of Drug Delivery Technology**
protecting drugs from the outside environment and guiding them directly to the target cancer cells
-  **Overcoming Treatment Resistance**
identification of a drug that could be beneficial for ovarian cancer patients whose cancer has grown after treatment
-  **Predicting Treatment Response**
identification of gene signatures associated with mesothelioma prognosis to help determine response to therapy

ACS CAN urges Congress to provide:

To ensure that the research being supported today yields the cancer treatments of tomorrow, Congress must sustain and expand the support it is currently providing.



[1] American Cancer Society. Cancer Facts and Figures 2025. Atlanta: American Cancer Society; 2025.
[2] United For Medical Research. 2025 NIH's Role in Sustaining the U.S. Economy. from: https://www.unitedformedicalresearch.org/wp-content/uploads/2025/03/UMR_NIH-Role-in-Sustaining-US-Economy-FY2024-2025-Update.pdf
[3] National Cancer Institute: Annual Plan & Budget Proposal for Fiscal Year 2025. Retrieved on April 11, 2024, from: <https://www.cancer.gov/research/annual-plan/2024-annual-plan-budget-proposal-aag.pdf>
[4] CCR Milestones: Annual Highlights 2024. Retrieved on April 11, 2024, from: <https://ccr.cancer.gov/news/milestones-2024/flippingbook>